The candidate lytic drug (Stachybotrys microspora triprenyl phenols (SMTP), TMS-007, is a plasminogen modulator composed of mevalonic acid and amino acids. Different to tPA, the compound integrates into the thrombus, promoting its dissolution. The company behind TMS-007 is TIMS Co., a spin-out of Tokyo University of Agriculture and Technology and Daihatsu Venture.
Nikkei Biotech news release, October 6, 2010
SMTP cerebral infarction drug candidate reaches Phase II